X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1829) 1829
Publication (77) 77
Book Review (21) 21
Book Chapter (7) 7
Newsletter (7) 7
Magazine Article (6) 6
Conference Proceeding (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1589) 1589
clonazepam - therapeutic use (1332) 1332
male (964) 964
female (904) 904
adult (681) 681
clonazepam (595) 595
middle aged (530) 530
anticonvulsants - therapeutic use (460) 460
clinical neurology (399) 399
psychiatry (385) 385
index medicus (319) 319
aged (287) 287
adolescent (264) 264
pharmacology & pharmacy (241) 241
child (224) 224
electroencephalography (218) 218
treatment outcome (217) 217
drug therapy, combination (209) 209
epilepsy - drug therapy (186) 186
clonazepam - adverse effects (184) 184
benzodiazepinones - therapeutic use (182) 182
neurosciences (176) 176
clonazepam - administration & dosage (175) 175
valproic acid - therapeutic use (171) 171
gaba modulators - therapeutic use (166) 166
animals (159) 159
benzodiazepines (149) 149
child, preschool (138) 138
double-blind (116) 116
epilepsy (112) 112
benzodiazepines - therapeutic use (110) 110
carbamazepine - therapeutic use (108) 108
dose-response relationship, drug (107) 107
myoclonus - drug therapy (102) 102
antipsychotic agents - therapeutic use (101) 101
double-blind method (100) 100
infant (99) 99
clonazepam - pharmacology (96) 96
diagnosis, differential (94) 94
diazepam - therapeutic use (87) 87
alprazolam (86) 86
bipolar disorder - drug therapy (85) 85
anti-anxiety agents - therapeutic use (82) 82
electromyography (80) 80
polysomnography (80) 80
follow-up studies (79) 79
phenobarbital - therapeutic use (79) 79
clinical trials as topic (76) 76
medicine, general & internal (74) 74
neurology (74) 74
phenytoin - therapeutic use (73) 73
seizures (73) 73
panic disorder - drug therapy (71) 71
sleep (71) 71
antipsychotic agents - adverse effects (70) 70
j ve psychiatry (70) 70
rats (70) 70
anxiety (69) 69
panic disorder (69) 69
seizures - drug therapy (69) 69
children (68) 68
time factors (67) 67
diazepam (66) 66
placebo (66) 66
anticonvulsants - adverse effects (65) 65
care and treatment (65) 65
psychiatric status rating scales (65) 65
serotonin uptake inhibitors - therapeutic use (65) 65
drug therapy (64) 64
anticonvulsants - administration & dosage (63) 63
magnetic resonance imaging (63) 63
carbamazepine (58) 58
pediatrics (58) 58
mice (57) 57
therapy (57) 57
efficacy (56) 56
anticonvulsants (55) 55
drug interactions (55) 55
restless legs syndrome - drug therapy (55) 55
drugs (54) 54
anxiety disorders - drug therapy (53) 53
phobic disorders - drug therapy (52) 52
retrospective studies (52) 52
drug administration schedule (51) 51
clonazepam - blood (50) 50
syndrome (50) 50
comorbidity (49) 49
infant, newborn (49) 49
aged, 80 and over (48) 48
diagnosis (48) 48
prevalence (48) 48
depression (47) 47
epilepsies, myoclonic - drug therapy (46) 46
status epilepticus - drug therapy (46) 46
young adult (46) 46
management (45) 45
psychology, clinical (45) 45
depressive disorder - drug therapy (44) 44
myoclonus (44) 44
myoclonus - etiology (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1596) 1596
Japanese (47) 47
French (41) 41
German (35) 35
Spanish (34) 34
Russian (22) 22
Italian (19) 19
Danish (10) 10
Polish (10) 10
Dutch (6) 6
Portuguese (6) 6
Hungarian (4) 4
Swedish (4) 4
Czech (3) 3
Finnish (3) 3
Chinese (2) 2
Norwegian (2) 2
Romanian (2) 2
Croatian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Psychiatry and Clinical Neurosciences, ISSN 1323-1316, 06/2015, Volume 69, Issue 6, pp. 321 - 334
Tardive dyskinesia is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking... 
first‐generation agents | schizophrenia | management | second‐generation agents | tardive dyskinesia | second-generation agents | first-generation agents | VITAMIN-E TREATMENT | NEUROTROPHIC FACTOR LEVELS | SCHIZOPHRENIC-PATIENTS | PSYCHIATRY | GINKGO-BILOBA | CHAIN AMINO-ACIDS | NEUROSCIENCES | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | HYPERKINETIC MOVEMENT-DISORDERS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ESSENTIAL FATTY-ACIDS | Stilbenes - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Propranolol - therapeutic use | Leucine - therapeutic use | Dopamine Agents - therapeutic use | Amantadine - therapeutic use | Piracetam - therapeutic use | Pyridoxine - therapeutic use | Clonazepam - therapeutic use | Drugs, Chinese Herbal - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Anticonvulsants - therapeutic use | Nootropic Agents - therapeutic use | Isoleucine - therapeutic use | Vitamins - therapeutic use | Ginkgo biloba | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Movement Disorders - etiology | Piracetam - analogs & derivatives | Melatonin - therapeutic use | Fatty Acids, Omega-3 - therapeutic use | Valine - therapeutic use | Isoxazoles - therapeutic use | Plant Extracts - therapeutic use | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use | Schizophrenia | Movement disorders | Tardive dyskinesia | Medical research
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 09/2010, Volume 71, Issue 9, pp. 1176 - 1186
Journal Article
The Journal of Neuropsychiatry and Clinical Neurosciences, ISSN 0895-0172, 01/2010, Volume 22, Issue 1, pp. 8 - 18
This manuscript reviews the preclinical in vitro, ex vivo, and nonhuman in vivo effects of psychopharmacological agents in clinical use on cell physiology with... 
TRIALS | APOPTOSIS | DEMENTIA | PSYCHIATRY | ALZHEIMERS-DISEASE | NEUROSCIENCES | CLINICAL NEUROLOGY | PARKINSONS-DISEASE | Neuroprotective Agents - therapeutic use | Humans | Dopamine Agonists - therapeutic use | Parkinson Disease - drug therapy | Neurodegenerative Diseases - drug therapy | Valproic Acid - pharmacology | Desipramine - pharmacology | Dibenzothiazepines - therapeutic use | Neuroprotective Agents - pharmacology | Desipramine - therapeutic use | Antipsychotic Agents - therapeutic use | Amyloid beta-Peptides - metabolism | Valproic Acid - therapeutic use | Parkinson Disease - metabolism | Clonazepam - therapeutic use | Maprotiline - pharmacology | Dopamine Agonists - pharmacology | Benzodiazepines - pharmacology | Benzothiazoles - pharmacology | Brain - physiopathology | Dibenzothiazepines - pharmacology | Quetiapine Fumarate | Serotonin Uptake Inhibitors - therapeutic use | Alzheimer Disease - drug therapy | Clonazepam - pharmacology | Neurodegenerative Diseases - metabolism | Brain - drug effects | Lithium Carbonate - therapeutic use | Antioxidants - therapeutic use | Neurodegenerative Diseases - physiopathology | Lithium Carbonate - pharmacology | Alzheimer Disease - metabolism | Melatonin - therapeutic use | Benzothiazoles - therapeutic use | Maprotiline - therapeutic use | Antipsychotic Agents - pharmacology | Serotonin Uptake Inhibitors - pharmacology | Benzodiazepines - therapeutic use
Journal Article
Journal Article
Journal of Clinical Sleep Medicine, ISSN 1550-9389, 02/2010, Volume 6, Issue 1, pp. 85 - 95
of Recommendations: Modifying the sleep environment is recommended for the treatment of patients with RBD who have sleep-related injury. Level A Clonazepam is... 
Paroxetine | Melatonin | Desipramine | Benzodiazepine | Clozapine | Clonazepam | Sleep-related injury | Sodium oxybate | Carbamazepine | Pramipexole | REM sleep behavior disorder | Zopiclone | Acetylcholinesterase inhibitor | Synucleinopathy | L-DOPA | Yi-Gan San | synucleinopathy | NEURODEGENERATIVE DISEASE | DEMENTIA | pramipexole | ALZHEIMERS-DISEASE | DOPAMINE TRANSPORTERS | sleep-related injury | desipramine | CLINICAL NEUROLOGY | DELAYED EMERGENCE | sodium oxybate | STATUS DISSOCIATUS | clonazepam | benzodiazepine | PARKINSONS-DISEASE | LEWY-BODY DISEASE | zopiclone | acetylcholinesterase inhibitor | DRUG-TREATMENT | carbamazepine | paroxetine | clozapine | EYE-MOVEMENT SLEEP | melatonin | Clonazepam - administration & dosage | REM Sleep Behavior Disorder - therapy | Central Nervous System Depressants - adverse effects | Humans | Dopamine Agonists - therapeutic use | GABA Modulators - administration & dosage | GABA Modulators - adverse effects | Dopamine Agonists - adverse effects | GABA Modulators - therapeutic use | Melatonin - administration & dosage | REM Sleep Behavior Disorder - drug therapy | Melatonin - adverse effects | Clonazepam - adverse effects | Central Nervous System Depressants - therapeutic use | Central Nervous System Depressants - administration & dosage | Dopamine Agonists - administration & dosage | Melatonin - therapeutic use | Benzothiazoles - therapeutic use | Clonazepam - therapeutic use | Benzothiazoles - adverse effects | REM Sleep Behavior Disorder - diagnosis | Benzothiazoles - administration & dosage | Special
Journal Article